In this interactive, enduring multimedia activity based on a 2015 American Society of Hematology Satellite Symposium, experts in hematology/oncology, infectious diseases, and pharmacy discuss optimal strategies to prevent and treat invasive mycoses in hematologic malignancy patients. This initiative features both video and text-based presentations of key epidemiologic data, diagnostic and therapeutic options, pharmacologic considerations, and guidelines/expert opinion on strategies to decrease the spectre of invasive fungal infections for patients with hematologic malignancies. It features in-depth discussion of real-world issues encountered in optimizing therapy and an international, esteemed faculty.
Release Date: 4/11/2016
Expiration Date: 4/10/2017
Estimated Time to Complete the Activity: 2 hrs
Media: Interactive presentation
If improperly managed, invasive fungal infections (IFIs) can sabotage cancer therapeutic efforts, leading to increased morbidity and mortality for patients with hematologic malignancies. Fortunately, the recent literature regarding IFI management in this setting has grown, and new advances have been made in IFI diagnostics and therapeutics. However, hematologist/oncologists and oncology pharmacists receive very little targeted education about IFI management in the setting of hematologic malignancies. I am pleased to moderate this discussion with my infectious diseases colleagues to address the latest updates on IFI diagnostics, therapeutics, and overall management strategies, with a specific focus on pharmacologic principles for optimal management as well as collaborative approaches for challenging cases. The activity is designed to assist you in addressing this important ID issue for your immunocompromised patients, enlisting sound principles and multidisciplinary management strategies to improve patient survival rates and other health outcomes.
After completing this activity, the participants should be better able to:
This activity is designed to meet the educational needs of hematologist/oncologists, pharmacists, infectious disease physicians, and others involved in the care of patients with hematologic malignancies at risk for or diagnosed with IFIs.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Medical Education,Terranova Medica, LLC, and the Mycoses Study Group Education & Research Consortium.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All faculty, planning committee members and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in these activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
MATTHEW A. LUNNING, DO
ADVISOR/CONSULTANT:
Alexion; Celgene; Genentech, Inc; Gilead Sciences, Inc.; Juno; Spectrum Pharmaceuticals, Inc.; TG Therapeutics
ERIC J. BOW, MD, MSc, D. Bacteriol, FRCPC
CONSULTANT:
Gilead Sciences; Gly-Pharma; Pfizer
REVIEW PANEL MEMBER:
Astellas
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs
ALISON G. FREIFELD, MD
DATA SAFETY MONITORING BOARD:
Astellas Pharma Global Development; Merck & Co., Inc.
JAMES S. LEWIS, II, PharmD, FIDSA
CONSULTANT:
Accelerate Diagnostics; Astellas; Cubist; Merck & Co., Inc.; Theravance Inc.
LOIS COLBURN
UNMC Center for Continuing Education
No conflicts to disclose.
BRENDA C. RAM, CMP, CHCP
UNMC Center for Continuing Education
No conflicts to disclose.
ANDREA ZIMMER, MD
No conflicts to disclose.
LISA A. TUSHLA, PHD, H(ASCP)
Terranova Medica, LLC
No conflicts to disclose
To receive a CME certificate of participation, participants should:
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser, Safari (version 6 or greater) web browser, or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred), and cookies MUST be enabled on your browser.
Terranova Medica, LLC, and UNMC CCE are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
To earn CME credits using the website, the UNMC CCE requires submission of certain personally identifiable information. The required items include: first name, last name, degree, and e-mail address. These items are necessary to award and track the credits that participants may earn after completing the program. To obtain credit, learners must complete an evaluation of the CME activity. This information is used in a continuous improvement process to enhance the learning experience of future programs.
Terranova Medica, LLC, and UNMC CCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing Education; the Mycoses Study Group Education & Research Consortium; and Terranova Medica, LLC.
Healthcare professionals and other individuals should review and consider other publications and materials on the subject before relying solely upon the information contained within this educational activity.
There is no charge for this activity.
This activity is supported by independent educational grants from: Astellas and Merck & Co, Inc.
For further information you may also contact Tom Davis by telephone or fax at 877-276-4523 or by email at tdavis@terranovamedica.com.
Copyright ©2016 UNMC CCE; Terranova Medica, LLC; and MSG-ERC.